Selegiline‐induced postural hypotension in Parkinson's disease: A longitudinal study on the effects of drug withdrawal
Identifieur interne : 004C42 ( Main/Exploration ); précédent : 004C41; suivant : 004C43Selegiline‐induced postural hypotension in Parkinson's disease: A longitudinal study on the effects of drug withdrawal
Auteurs : A. Churchyard [Royaume-Uni] ; C. J. Mathias [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 1999-03.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Aged, Analysis of Variance, Antiparkinson Agents (adverse effects), Antiparkinson agent, Blood Pressure (drug effects), Chemotherapy, Combined treatment, Dizziness (chemically induced), Drug Therapy, Combination, Epinephrine (blood), Female, Head, Heart Rate (drug effects), Human, Humans, Hypotension, Orthostatic (chemically induced), Levodopa, Male, Middle Aged, Norepinephrine (blood), Orthostatic hypotension, Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Postural hypotension, Posture (physiology), Prospective Studies, Selegiline, Selegiline (adverse effects), Severity of Illness Index, Substance Withdrawal Syndrome (physiopathology), Time Factors, Toxicity.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Selegiline.
- chemical , blood : Epinephrine, Norepinephrine.
- chemically induced : Dizziness, Hypotension, Orthostatic.
- drug effects : Blood Pressure, Heart Rate.
- drug therapy : Parkinson Disease.
- physiology : Posture.
- physiopathology : Substance Withdrawal Syndrome.
- Aged, Analysis of Variance, Drug Therapy, Combination, Female, Head, Humans, Male, Middle Aged, Prospective Studies, Severity of Illness Index, Time Factors.
Abstract
OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L‐dopa compared with those taking L‐dopa alone. Recently, we found that therapy with selegiline and L‐dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline. This unwanted effect on postural blood pressure was not the result of underlying autonomic failure. The aims of this study were to confirm our previous findings in a separate cohort of patients and to determine the time course of the cardiovascular consequences of stopping selegiline in the expectation that this might shed light on the mechanisms by which the drug causes orthostatic hypotension. METHODS: The cardiovascular responses to standing and head‐up tilt were studied repeatedly in PD patients receiving selegiline and as the drug was withdrawn. RESULTS: Head‐up tilt caused systolic orthostatic hypotension which was marked in six of 20 PD patients on selegiline, one of whom lost consciousness with unrecordable blood pressures. A lesser degree of orthostatic hypotension occurred with standing. Orthostatic hypotension was ameliorated 4 days after withdrawal of selegiline and totally abolished 7 days after discontinuation of the drug. Stopping selegiline also significantly reduced the supine systolic and diastolic blood pressures consistent with a previously undescribed supine pressor action. CONCLUSION: This study confirms our previous finding that selegiline in combination with L‐dopa is associated with selective orthostatic hypotension. The possibilities that these cardiovascular findings might be the result of non‐selective inhibition of monoamine oxidase or of amphetamine and met‐amphetamine are discussed.
Url:
DOI: 10.1002/1531-8257(199903)14:2<246::AID-MDS1008>3.0.CO;2-P
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000F38
- to stream Istex, to step Curation: 000F38
- to stream Istex, to step Checkpoint: 003409
- to stream Main, to step Merge: 007941
- to stream PascalFrancis, to step Corpus: 002E56
- to stream PascalFrancis, to step Curation: 003968
- to stream PascalFrancis, to step Checkpoint: 002D22
- to stream Main, to step Merge: 007B71
- to stream PubMed, to step Corpus: 004244
- to stream PubMed, to step Curation: 004244
- to stream PubMed, to step Checkpoint: 004107
- to stream Ncbi, to step Merge: 000007
- to stream Ncbi, to step Curation: 000007
- to stream Ncbi, to step Checkpoint: 000007
- to stream Main, to step Merge: 007714
- to stream Main, to step Curation: 004C42
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Selegiline‐induced postural hypotension in Parkinson's disease: A longitudinal study on the effects of drug withdrawal</title><author><name sortKey="Churchyard, A" sort="Churchyard, A" uniqKey="Churchyard A" first="A." last="Churchyard">A. Churchyard</name></author><author><name sortKey="Mathias, C J" sort="Mathias, C J" uniqKey="Mathias C" first="C. J." last="Mathias">C. J. Mathias</name></author><author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew Lees (neurologue)</name><affiliation><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName>National Hospital for Neurology and Neurosurgery</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9A908D5F2AF652920955967E433870A920559388</idno><date when="1999" year="1999">1999</date><idno type="doi">10.1002/1531-8257(199903)14:2<246::AID-MDS1008>3.0.CO;2-P</idno><idno type="url">https://api.istex.fr/document/9A908D5F2AF652920955967E433870A920559388/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000F38</idno><idno type="wicri:Area/Istex/Curation">000F38</idno><idno type="wicri:Area/Istex/Checkpoint">003409</idno><idno type="wicri:doubleKey">0885-3185:1999:Churchyard A:selegiline:induced:postural</idno><idno type="wicri:Area/Main/Merge">007941</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:99-0185792</idno><idno type="wicri:Area/PascalFrancis/Corpus">002E56</idno><idno type="wicri:Area/PascalFrancis/Curation">003968</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002D22</idno><idno type="wicri:doubleKey">0885-3185:1999:Churchyard A:selegiline:induced:postural</idno><idno type="wicri:Area/Main/Merge">007B71</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:10091617</idno><idno type="wicri:Area/PubMed/Corpus">004244</idno><idno type="wicri:Area/PubMed/Curation">004244</idno><idno type="wicri:Area/PubMed/Checkpoint">004107</idno><idno type="wicri:Area/Ncbi/Merge">000007</idno><idno type="wicri:Area/Ncbi/Curation">000007</idno><idno type="wicri:Area/Ncbi/Checkpoint">000007</idno><idno type="wicri:doubleKey">0885-3185:1999:Churchyard A:selegiline:induced:postural</idno><idno type="wicri:Area/Main/Merge">007714</idno><idno type="wicri:Area/Main/Curation">004C42</idno><idno type="wicri:Area/Main/Exploration">004C42</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Selegiline‐induced postural hypotension in Parkinson's disease: A longitudinal study on the effects of drug withdrawal</title><author><name sortKey="Churchyard, A" sort="Churchyard, A" uniqKey="Churchyard A" first="A." last="Churchyard">A. Churchyard</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neurology and University Department of Clinical Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Mathias, C J" sort="Mathias, C J" uniqKey="Mathias C" first="C. J." last="Mathias">C. J. Mathias</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neurology and University Department of Clinical Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew Lees (neurologue)</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neurology and University Department of Clinical Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName>National Hospital for Neurology and Neurosurgery</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="1999-03">1999-03</date><biblScope unit="vol">14</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="246">246</biblScope><biblScope unit="page" to="251">251</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">9A908D5F2AF652920955967E433870A920559388</idno><idno type="DOI">10.1002/1531-8257(199903)14:2<246::AID-MDS1008>3.0.CO;2-P</idno><idno type="ArticleID">MDS1008</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Analysis of Variance</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson agent</term><term>Blood Pressure (drug effects)</term><term>Chemotherapy</term><term>Combined treatment</term><term>Dizziness (chemically induced)</term><term>Drug Therapy, Combination</term><term>Epinephrine (blood)</term><term>Female</term><term>Head</term><term>Heart Rate (drug effects)</term><term>Human</term><term>Humans</term><term>Hypotension, Orthostatic (chemically induced)</term><term>Levodopa</term><term>Male</term><term>Middle Aged</term><term>Norepinephrine (blood)</term><term>Orthostatic hypotension</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Postural hypotension</term><term>Posture (physiology)</term><term>Prospective Studies</term><term>Selegiline</term><term>Selegiline (adverse effects)</term><term>Severity of Illness Index</term><term>Substance Withdrawal Syndrome (physiopathology)</term><term>Time Factors</term><term>Toxicity</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Selegiline</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Epinephrine</term><term>Norepinephrine</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Dizziness</term><term>Hypotension, Orthostatic</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Blood Pressure</term><term>Heart Rate</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Posture</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Substance Withdrawal Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Analysis of Variance</term><term>Drug Therapy, Combination</term><term>Female</term><term>Head</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term><term>Severity of Illness Index</term><term>Time Factors</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Antiparkinsonien</term><term>Chimiothérapie</term><term>Homme</term><term>Hypotension artérielle orthostatique</term><term>Lévodopa</term><term>Parkinson maladie</term><term>Sélégiline</term><term>Toxicité</term><term>Traitement associé</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L‐dopa compared with those taking L‐dopa alone. Recently, we found that therapy with selegiline and L‐dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline. This unwanted effect on postural blood pressure was not the result of underlying autonomic failure. The aims of this study were to confirm our previous findings in a separate cohort of patients and to determine the time course of the cardiovascular consequences of stopping selegiline in the expectation that this might shed light on the mechanisms by which the drug causes orthostatic hypotension. METHODS: The cardiovascular responses to standing and head‐up tilt were studied repeatedly in PD patients receiving selegiline and as the drug was withdrawn. RESULTS: Head‐up tilt caused systolic orthostatic hypotension which was marked in six of 20 PD patients on selegiline, one of whom lost consciousness with unrecordable blood pressures. A lesser degree of orthostatic hypotension occurred with standing. Orthostatic hypotension was ameliorated 4 days after withdrawal of selegiline and totally abolished 7 days after discontinuation of the drug. Stopping selegiline also significantly reduced the supine systolic and diastolic blood pressures consistent with a previously undescribed supine pressor action. CONCLUSION: This study confirms our previous finding that selegiline in combination with L‐dopa is associated with selective orthostatic hypotension. The possibilities that these cardiovascular findings might be the result of non‐selective inhibition of monoamine oxidase or of amphetamine and met‐amphetamine are discussed.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement><orgName><li>National Hospital for Neurology and Neurosurgery</li></orgName></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Churchyard, A" sort="Churchyard, A" uniqKey="Churchyard A" first="A." last="Churchyard">A. Churchyard</name></region><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew Lees (neurologue)</name><name sortKey="Mathias, C J" sort="Mathias, C J" uniqKey="Mathias C" first="C. J." last="Mathias">C. J. Mathias</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004C42 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004C42 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:9A908D5F2AF652920955967E433870A920559388
|texte= Selegiline‐induced postural hypotension in Parkinson's disease: A longitudinal study on the effects of drug withdrawal
}}
| This area was generated with Dilib version V0.6.23. |  |